Research into Rac GTPase Protein for CML

[Guest guest]

Hey Folks,

I haven't posted in a while. I've been quite busy with my life in general.

Hope everyone is well,

Cheers!

Cheryl-Anne

Grant to fund leukemia study at Children's

<http://www.bizjournals.com/search/bin/search?t=cincinnati & am=cincinnati & q=%

22%22 & f=byline & am=120_days & r=20>

The national chapter of the Leukemia & Lymphoma Society has awarded a

$600,000 grant to

<http://www.bizjournals.com/search/bin/search?q=%22Cincinnati%20Children's%2

0Hospital%20Medical%20Center%22 & t=cincinnati> Cincinnati Children's Hospital

Medical Center for a study to begin Oct. 1.

The " translational research " grant will fund the three-year study to be

conducted by Dr. A. , director of the Division of Experimental

Hematology and associate chairman for translational research for Cincinnati

Children's; Dr. Yi Zheng, program leader for the center's Signaling Program;

and Dr. Cancela, director of the center's Stem Cell Program in

Experimental Hematology and director of research for

<http://www.bizjournals.com/search/bin/search?q=%22Hoxworth%20Blood%20Center

%22 & t=cincinnati> Hoxworth Blood Center.

The grant will allow the researchers to study the effects of the Rac GTPase

protein in chronic myelogenous leukemia, or CML. They will modify or

eliminate the Rac protein both in test tubes and on mice to see the effect

on the progression of the disease.

The researchers' hypothesis is that elimination of the Rac protein in those

with this form of leukemia will slow the progression of the disease. If the

hypothesis is correct, the team is hopeful that an effective anti-CML drug

may be developed for the treatment of myelogenous leukemia patients.